The Cellular Culprits of Aging: Understanding Senescent Cells

As we age, the risk of developing chronic conditions like osteoporosis, diabetes, and Alzheimer’s disease increases. A key factor at the cellular level is the accumulation of senescent cells, frequently enough referred to as “zombie cells.” These damaged cells lose their ability to repair themselves and tend to persist in the body, contributing to age-related decline.

These “zombie cells” secrete inflammatory molecules, accelerating the aging process. This phenomenon has spurred research into therapies that target these cells, aiming to promote healthier aging.

Senolytics: A Potential Solution for Age-Related Diseases

Senolytics, a class of drugs and supplements, are being investigated for their potential to eliminate senescent cells or mitigate their harmful effects. This approach represents a promising avenue for addressing age-related diseases.

These cells have a very robust secretory phenotype. They are at the origin of factors such as the alteration of tissue regeneration, fibrosis, degeneration, inflammation … which are clearly linked to age-related diseases. This is what is exciting with these cells.

Nathan K. LeBrasseur, Director of the Robert and Arlene kogod Center on Aging at the Mayo Clinic

Beyond Longevity: Prioritizing Quality of Life

Researchers in the field of senolytics emphasize the importance of healthy aging rather then simply extending lifespan. The goal is to increase the number of active and productive years, minimizing the impact of illness and disability.

We really don’t want to make drugs that help us live untill the age of 120 and feel like they have 120. If we have no effect on life expectancy, there is no problem, but increase the number of active and productive years which are not to much increased by illness and inability.

Nathan K.lebrasseur, Director of the Robert and Arlene Kogod Center on Aging at the Mayo Clinic

Current Research and Clinical Trials

Since the initial discovery of senolytics in 2015, much of the research has been conducted on animal models, particularly mice. Early senolytic candidates,such as Navitoclax (ABT-263) and ABT-737,faced challenges due to adverse effects in humans and accelerated ovarian aging in mice.

currently, some existing chemotherapy drugs have demonstrated senolytic properties. Though,the options available for human use remain limited.

We do not have a pharmacy cabinet full of options in humans. There are some reassigned drugs that are subject to tests.

Nathan K. LeBrasseur, Director of the Robert and Arlene Kogod Center on Aging at the Mayo Clinic

Approximately 20 clinical trials are currently underway, with at least 10 more in the planning stages or having preliminary publications. These trials are exploring the potential of senolytics in treating conditions such as osteoarthritis, COVID-19, Alzheimer’s disease, and Parkinson’s disease.

Trials are underway on senolytics for osteoarthritis, COVID-19, Alzheimer’s disease and Parkinson’s disease.

Paul Robbins, Associate Director of the Masonic Institute on the Biology of Aging and Metabolism and professor at the University of Minnesota

One innovative approach involves treating grafts from elderly donors with senolytics before transplantation. Emerging evidence suggests that senolytics can reduce senescence in humans and offer additional benefits.

A notable trial by Unity biotechnology, published last year, showed promising results with a senolytic called Foselutocl.

The Future of Senolytics: Challenges and Opportunities

while the field of senolytics holds great promise, challenges remain in identifying safe and effective senolytic drugs for human use. Ongoing research and clinical trials are crucial for advancing our understanding of senescent cells and developing targeted therapies to promote healthy aging.

The potential benefits of senolytics extend beyond treating specific diseases. By targeting the fundamental processes of aging, these therapies could improve overall health and well-being, enabling individuals to live more active and fulfilling lives.

Targeting Cellular Senescence: A Promising Avenue for Combating Age-Related Diseases

As the global population ages, the quest for effective treatments for age-related diseases intensifies. Emerging research suggests that senolytic therapies, designed to eliminate senescent cells, hold significant promise in this arena. Senescent cells, often referred to as “zombie cells,” are cells that have stopped dividing but refuse to die, accumulating in tissues and contributing to inflammation and age-related dysfunction. Recent studies highlight the potential of senolytics in treating conditions ranging from diabetic macular edema to idiopathic pulmonary fibrosis.

Breakthrough in Vision Betterment: Senolytics for Diabetic Macular Edema

A novel approach involving a single injection of a senolytic drug directly into the eye has shown remarkable results in improving vision, particularly in low-light conditions, for individuals with advanced diabetic macular edema. This treatment, with effects lasting at least six months, functions by inhibiting a protein responsible for regulating cell death. Researchers believe this inhibition leads to the removal of senescent cells, thereby stimulating healing processes within the eye. This is particularly significant considering that diabetic macular edema is a leading cause of vision loss in adults with diabetes, affecting millions worldwide. According to the National Eye Institute, diabetic retinopathy, which includes macular edema, affects nearly 7.7 million Americans aged 40 years or older.

D+Q: A Senolytic Powerhouse

Another notable senolytic combination gaining traction is D+Q,a pairing of Dasatinib,an FDA-approved chemotherapy drug,and quercetin,a naturally occurring flavonoid found in various foods. Dasatinib selectively targets specific receptors on the surface of certain senescent cells, triggering a process of programmed cell death. As Nathan Lebraseur explains, In a way, it is indeed a question of extinguishing a switch in the cell, so that it dormant.

Preclinical studies conducted in 2017 and 2018 demonstrated that D+Q improved bone density, extended lifespan, and enhanced physical function in elderly mice. Ming Xu,Associate Professor at the University of Minnesota and co-author of these studies,noted that these findings laid the foundations for a number of clinical trials in progress. These trials are crucial in translating the promising results from animal models to human applications.

Clinical Trials Show Promise, Highlight Challenges

Early clinical trials have yielded encouraging results. A phase 1 trial revealed that intermittent doses of D+Q improved physical function in a small group of elderly individuals suffering from idiopathic pulmonary fibrosis, a severe lung disease. Furthermore, a phase 2 trial involving 60 healthy menopausal women indicated that D+Q promoted the formation of new bone tissue, although it did not reduce bone resorption, the breakdown of old bone tissue.

Interestingly, the study also revealed that women with the highest baseline biomarkers for senescent cell burden experienced the moast significant benefits from the D+Q treatment, exhibiting increased bone formation, decreased bone resorption, and improved bone mineral density in the wrist.This observation underscores the importance of patient selection in senolytic therapies. As Dr. Lebraseur points out, One of the challenges in our field is how to select peopel who best meet these interventions.

The Complexity of Senescent Cells: A Major Hurdle

Despite the promising potential of senolytics, significant challenges remain. One of the primary obstacles is the inherent heterogeneity of senescent cells. The sennet Consortium, a large-scale research network dedicated to mapping senescent cells in human tissues, has highlighted this complexity.

According to Professor Robbins, The task turned out to be colossal.A senescent cell in the kidney is different from that of the liver,which is different from that of the brain. Even within the same tissue, diverse subpopulations of senescent cells can exist, with seemingly unrelated cells sharing senescence characteristics, according to Professor Xu.

adding another layer of complexity,not all senescent cells are detrimental. Some play crucial roles in tumor suppression, wound healing, and tissue repair. We have no good markers to distinguish them, explains Paul Robbins. But it seems that, in terms of functional level, the treatment of an elderly animal by senolytics is beneficial. In juvenile animals, data is contradictory as to the positive or negative effects of an attempt to eliminate these cells.

Future Directions: Precision Senolytics and Personalized Medicine

The future of senolytic therapies lies in developing more precise and targeted approaches. Researchers are actively working to identify specific markers that can differentiate between beneficial and harmful senescent cells. This will pave the way for personalized senolytic treatments tailored to individual patient profiles and disease contexts. As our understanding of cellular senescence deepens, senolytic therapies hold the potential to revolutionize the treatment of age-related diseases and improve the healthspan of individuals worldwide.

The Promise of Senolytics: Targeting Cellular Aging

The quest for extending human lifespan and combating age-related diseases has led researchers down many paths. One particularly promising avenue involves senolytics – compounds designed to selectively eliminate senescent cells, those that have stopped dividing and accumulate with age, contributing to tissue dysfunction and various ailments.

A Cocktail Approach: Multiple Senolytics for Complex Aging

current research explores a variety of senolytic options, ranging from chemotherapy drugs and senolytic cell inhibitors to immunotherapies.Scientists like paul Robbins are investigating senolytic lipids, RNA-based therapies, and natural senolytic compounds. Notably, Fisetin, a flavonoid found in many fruits and vegetables, is currently undergoing phase 2 clinical trials to assess its potential in mitigating severe COVID-19 symptoms.

Professor Robbins suggests that different senolytics may target distinct classes of senescent cells. This implies that a combination, or cocktail, of senolytics might be necessary to address the multifaceted nature of aging. Such a cocktail could be used proactively to maintain overall health rather than targeting specific diseases like Alzheimer’s.

there will not be only one triumphant senolytic, but perhaps several different senolytics.

Felix Wong, PhD, Co-founder of Biotechnology Society integrated Biosciences

Felix wong, PhD, co-founder of Biotechnology Society Integrated Biosciences, echoes this sentiment. His team, two years prior, employed deep learning to identify three potential senolytic compounds from a vast database of 800,000 molecules. They trained a graph neural network, a type of artificial intelligence model, to predict senolytic activity based solely on chemical structure. When administered to elderly mice, these compounds effectively reduced the accumulation of senescent cells.

Challenges and Future Directions

While the research shows promise,clinical applications are still some time away.Dr. Wong notes that Integrated Biosciences is continuing to investigate disease models where these compounds could prove effective.

A significant hurdle is regulatory approval. The FDA does not recognize aging as a disease, it will therefore be necessary to seek a specific indication, Dr. Wong stated. This means researchers must target specific age-related diseases to gain approval for senolytic therapies.

However, there are encouraging signs. The advanced Research Projects agency for Health (ARPA-H), a US agency, launched the Proactive Solutions for Prolonging Resilience (ProSPR) program. This initiative aims to deepen our understanding of the underlying causes of age-related diseases and develop therapies to extend lifespan and prevent their onset. This could pave the way for more extensive testing of drugs targeting aging.

Despite these advancements, nathan Lebraseur estimates that it will take at least a decade before we can definitively determine the efficacy of senolytics.

Beyond Senolytics: A Holistic Approach to Longevity

While pharmacological interventions like senolytics hold great potential,its crucial to remember the importance of lifestyle factors. Nutritional and physical activity interventions remain fundamental pillars of healthy aging. For example, regular exercise has been shown to improve cardiovascular health, cognitive function, and overall well-being in older adults.Similarly, a balanced diet rich in fruits, vegetables, and whole grains can help reduce the risk of chronic diseases.

the advancement of senolytic therapies represents a significant step forward in our understanding of aging and our ability to intervene in the aging process. As research progresses and clinical trials yield results, we might potentially be on the cusp of a new era in preventative medicine, where targeting cellular senescence becomes a key strategy for extending healthspan and improving the quality of life for older adults.

The Power of Movement: Physical Activity as an Anti-Aging Strategy

Emerging research underscores the profound impact of physical activity on slowing down the aging process. Dr. Lebraseur’s work highlights that even modest increases in daily movement, such as regular walking and reducing sedentary behavior, are associated with lower levels of senescence biomarkers in older adults (ages 70-80). This suggests that incorporating more movement into daily routines can be a powerful tool in promoting healthy aging.

Beyond simply slowing down aging, physical activity plays a crucial role in optimizing overall health and immune function. A growing body of evidence indicates that exercise creates a more favorable surroundings within the body, allowing immune cells to more effectively identify and eliminate senescent cells – cells that contribute to age-related decline. According to the World health Institution (WHO), adults aged 65 and older should aim for at least 150 minutes of moderate-intensity aerobic activity or 75 minutes of vigorous-intensity activity per week for ample health benefits.

GLP-1 Agonists: A Paradigm Shift in Anti-Aging research?

While initially recognized for their effectiveness in treating obesity and type 2 diabetes, glucagon-Like Peptide 1 (GLP-1) agonists are now demonstrating potential benefits in addressing neurodegenerative and renal diseases associated with aging. dr.Wong suggests that the observed “anti-aging” properties of GLP-1 agonists represent a significant shift in how we approach age-related conditions.

The mechanisms behind these potential anti-aging effects are still being investigated, but research suggests that GLP-1 agonists may protect against cellular damage and inflammation, both of which are key contributors to the aging process. Further studies are needed to fully understand the long-term effects and optimal use of GLP-1 agonists in promoting healthy aging.

senolytics: A Promising but Cautious Approach

Senolytics, compounds designed to selectively eliminate senescent cells, have garnered significant attention as a potential therapeutic strategy for age-related diseases. In 2023, the National Academy of Medicine acknowledged the importance of geoscience research, including senolytics, for public health, given the burden of chronic diseases linked to aging. They emphasized the need to support this research, particularly in identifying relevant biomarkers to track the effectiveness of senolytic interventions.

Though, the National Academy of Medicine also cautioned that senolytic research is still in its early stages. Cellular senescence serves as a defense mechanism against cancer, and therefore, interventions targeting cellular aging must be carefully evaluated for potential adverse effects on tissue regeneration and cancer risk. The Academy stressed that only conclusive results from large,randomized,and controlled clinical trials can validate the therapeutic potential of senolytics for chronic diseases. Furthermore, the ethical implications of using senolytics to prevent age-related diseases or even extend lifespan must be thoroughly examined before widespread adoption.

Only conclusive results of large randomized and controlled clinical trials could validate the therapeutic potential of senolytics for chronic diseases. The ethical questions, posed by the use of senolytics, without major side effects, for the prevention of the pathological consequences of aging, even to extend the duration of life, must be, beforehand, in -depth.

National Academy of Medicine, 2023

The Future of Anti-Aging Interventions

While the quest for effective anti-aging interventions is ongoing, the current research landscape offers promising avenues for promoting healthy aging. From the simple yet powerful impact of physical activity to the potential of GLP-1 agonists and the targeted approach of senolytics, scientists are making strides in understanding and addressing the complexities of aging. However, rigorous research, careful consideration of potential risks, and thorough ethical evaluation are essential to ensure that these interventions are safe, effective, and beneficial for all.